Publication | Closed Access

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Hematological MalignancyLymphoid NeoplasiaRituximab Versus RituximabMedicineRandomised Phase 3Follicular LymphomaPathologyOncologyRadiation Oncology